40
Participants
Start Date
June 16, 2021
Primary Completion Date
April 15, 2022
Study Completion Date
June 10, 2022
CBP-201
CBP-201 subcutaneous (SC) injection.
Placebo
Placebo subcutaneous (SC) injection.
Connect Investigative Site 503, Kyiv
Connect Investigative Site 502, Kyiv
Connect Investigative Site 505, Kyiv
Connect Investigative Site 113, The Bronx
Connect Investigative Site 105, Rochester
Connect Investigative Site 110, White Marsh
Connect Investigative Site 118, Norfolk
Connect Investigative Site 117, Winston-Salem
Connect Investigative Site 601, Madrid
Connect Investigative Site 108, Charleston
Connect Investigative Site 311, Taiyuan
Connect Investigative Site 114, Miami
Connect Investigative Site 109, Miami
Connect Investigative Site 116, Tampa
Connect Investigative Site 130, Birmingham
Connect Investigative Site 506, Poltava
Connect Investigative Site 107, Memphis
Connect Investigative Site 132, Louisville
Connect Investigative Site 603, Seville
Connect Investigative Site 504, Lutsk
Connect Investigative Site 133, Columbus
Connect Investigative Site 123, Cincinnati
Connect Investigative Site 501, Dnipropetrovsk
Connect Investigative Site 111, Chicago
Connect Investigative Site 126, Chicago
Connect Investigative Site 509, Kharkiv
Connect Investigative Site 127, St Louis
Connect Investigative Site 112, Tulsa
Connect Investigative Site 122, Tulsa
Connect Investigative Site 101, Sherman
Connect Investigative Site 104, Dallas
Connect Investigative Site 106, Austin
Connect Investigative Site 507, Ivano-Frankivsk
Connect Investigative Site 508, Ivano-Frankivsk
Connect Investigative Site 510, Ivano-Frankivsk
Connect Investigative Site 120, Houston
Connect Investigative Site 129, St. George
Connect Investigative Site 134, Los Angeles
Connect Investigative Site 119, Torrance
Connect Investigative Site 125, La Mesa
Connect Investigative Site 128, Temecula
Connect Investigative Site 124, Bakersfield
Connect Investigative Site 115, Bellingham
Connect Investigative Site 313, Shenyang
Connect Investigative Site 301, Shanghai
Connect Investigative Site 312, Shanghai
Connect Investigative Site 306, Nanjing
Connect Investigative Site 308, Yangzhou
Connect Investigative Site 307, Bengbu
Connect Investigative Site 304, Qingdao
Connect Investigative Site 310, Hangzhou
Connect Investigative Site 303, Chongqing
Connect Investigative Site 309, Jingzhou
Connect Investigative Site 302, Nanning
Connect Investigative Site 305, Xi’an
Connect Investigative Site 121, Ann Arbor
Connect Investigative Site 102, Princeton
Connect Investigative Site 401, Bydgoszcz
Connect Investigative Site 407, Krakow
Connect Investigative Site 402, Krakow
Connect Investigative Site 409, Lubin
Connect Investigative Site 408, Warsaw
Connect Investigative Site 403, Warsaw
Connect Investigative Site 405, Rzeszów
Connect Investigative Site 404, Bialystok
Connect Investigative Site 406, Zabrze
Connect Investigative Site 604, Barcelona
Connect Investigative Site 602, Córdoba
Lead Sponsor
Connect Biopharm LLC
INDUSTRY